Fortune November 8, 2023
Eli Lilly’s diabetes drug tirzepatide gained US approval for treating patients with obesity under a new name, Zepbound, unlocking blockbuster sales potential in a market that’s expected to hit $100 billion by 2030.
“In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need,” the US Food and Drug Administration said in a statement Wednesday.
In a statement, the company said the drug would be sold at a slight premium to the price of the diabetes version of the same medication, sold as Mounjaro. The weight-loss drug will list for $1,059.87 for a...
Today's Sponsors
Today's Sponsor